As an Amazon Associate, we earn from qualifying purchases. This post may contain affiliate links.
By Luis Gustavo. See how we research and review our content.
In late August 2026, a preliminary study made headlines among sleep researchers and nightly melatonin users alike: people with chronic insomnia who used melatonin long-term showed a roughly 90% higher risk of developing heart failure over five years of follow-up, compared with those who had insomnia but didn’t use the supplement long-term. That’s a number that grabs attention on first read — and melatonin has quietly become one of the best-selling supplements in the world, taken nightly by plenty of people who don’t even have a formal insomnia diagnosis, just a habit of reaching for it whenever a rough night looms. That’s exactly why it’s worth slowing down to look at what this number actually shows, what it doesn’t prove, and what to reasonably do with it without either panicking or shrugging it off.
Inside the numbers: what the 2026 study actually tracked
The study compared two groups of people who already had diagnosed chronic insomnia: those who used melatonin continuously, night after night, over an extended period, and those who didn’t use it that way. Over five years of follow-up, the long-term-use group showed roughly a 90% higher incidence of heart failure. This kind of design — observational, following people over time without controlling who takes what, the way a lab experiment would — is called a cohort study, and it’s a genuinely valuable tool in medical research, but it comes with real limits that matter before drawing any firm conclusion. Full methodological details, including the exact cohort size and the complete peer-reviewed writeup, were still rolling out as the finding gained attention, which is common for freshly announced research. The researchers behind the finding themselves described it as preliminary and called for further research to confirm and better understand the relationship — a sign this isn’t a closed case but the opening of a line of inquiry.
Correlation isn’t causation — and here’s what that distinction really means
This is arguably the most important section in the entire article, so it’s worth slowing down here. When an observational study finds an association — “people who use X have a higher chance of Y” — it means the two things show up together more often than chance would predict. That is not the same as proving one causes the other. A classic example used to teach this difference: cities that sell more ice cream also see more drownings in the same stretch of time, but nobody would say ice cream causes drowning — the real factor behind both is summer heat, which drives up both ice cream sales and trips to the pool. To establish cause and effect with real confidence, science generally needs randomized controlled trials, where similar people are randomly assigned to take or not take a substance, which strips out much of what could otherwise muddy the result. A trial like that, testing melatonin against heart failure outcomes at scale, simply doesn’t exist yet. None of this makes the association meaningless — it’s a real signal worth serious investigation — but stating that “melatonin causes heart failure” goes further than the current data can support, and that overreach is exactly what careful science reporting tries to avoid.
The obvious confounder: chronic insomnia already strains the heart
There’s a plausible alternative explanation that any solid study needs to try to rule out. People with chronic insomnia, as a group, already carry elevated cardiovascular risk factors before any supplement enters the picture. Long-term poor sleep is well documented to correlate with higher blood pressure, elevated systemic inflammation, insulin resistance, and greater strain on the autonomic nervous system — all factors that independently work against heart health. This is what researchers call a confounding variable: it’s possible that some, or even most, of the elevated risk seen in the melatonin-using group actually traces back to how severe their underlying chronic insomnia was, rather than to the substance itself. There’s also a second possibility worth naming, called reverse causation: people whose insomnia is already more severe, often because of a cardiovascular system that’s already under more strain, may be exactly the ones most likely to reach for melatonin long-term in the first place, which would flip the arrow the headline implies. Teasing those hypotheses apart with precision is exactly the kind of work follow-up studies will need to do next — typically through statistical adjustments that try to isolate melatonin’s effect from the effect of insomnia severity itself, by comparing patients with similarly severe cases, or by following the same individuals for even longer to see whether risk shifts as dose and duration of use vary.
Melatonin isn’t a sedative — it’s a timing signal
Much of the confusion around melatonin comes from a basic misunderstanding of what it actually does in the body. Melatonin is a hormone produced naturally by the pineal gland in the brain, and its release is governed by the light-dark cycle detected by the eyes: production rises as it gets dark and is suppressed by light exposure, including the blue light from phone and computer screens. It works by binding to specific receptors (known as MT1 and MT2) scattered across the brain and other tissues, helping synchronize the internal circadian clock with the external day-night cycle. It doesn’t “switch off” the brain the way a sedative does — its real job is to signal to the body that it’s time to prepare for sleep, not to force unconsciousness. It’s also worth noting that natural melatonin production tends to decline with age, one reason older adults report more trouble sleeping and, in turn, lean more heavily on the supplement. That’s why melatonin tends to work well for shifting the timing of sleep, but not necessarily for forcing sleep to happen against the body’s own rhythm. Understanding that distinction resets expectations: taking melatonin and expecting the immediate knockout effect of a sleeping pill is, technically, asking it to do a job it was never built for. It also explains why some people feel little to no effect from a standard dose while others feel groggy the next morning — timing relative to a person’s own circadian rhythm, and how much light exposure surrounds the dose, tends to matter as much as the amount taken.
What’s actually in the bottle: the supplement-label accuracy problem
Unlike prescription sleep medications, melatonin is sold over the counter as a dietary supplement in the US and in most of the world, which means it isn’t held to the same rigorous regulatory testing that pharmaceutical drugs go through before reaching shelves — there’s no requirement, for instance, that every production batch be independently verified to contain exactly the dose stated on the label. Independent lab testing has repeatedly found that the actual melatonin content in many commercial products doesn’t match what’s printed on the label — sometimes containing less than advertised, sometimes significantly more, and occasionally carrying contaminants that don’t appear on the ingredient list at all. Add to that another under-discussed detail: many products on the market contain melatonin doses three to ten times higher than the amounts shown to be effective in research, which typically falls in the range of half a milligram to a few milligrams, while commercial capsules routinely run 5, 10, or more milligrams per dose. That means a meaningful share of users have no clear idea how much they’re actually taking each night, let alone whether that dose fits their individual situation — a detail that becomes even more relevant in light of any research trying to connect dose with health risk.
A jet-lag pill taken nightly for years is a different experiment entirely
Most of the solid scientific evidence behind melatonin concerns short-term, situational use: resetting the body clock after a long-haul flight across time zones (classic jet lag), adjusting to a new work shift schedule, or realigning sleep timing for people with delayed sleep phase, a pattern more common among teenagers and young adults. For those cases, the hormone has a well-established, well-studied role, typically used for a few days or weeks until the internal clock resets. Nightly, continuous use for months or years, as a general treatment for chronic insomnia, is a very different story — and a far less studied one. A large share of today’s popular melatonin use actually falls into that second category, a use pattern most sleep specialists never originally recommended as a long-term strategy, simply because the safety and efficacy research for that specific scenario has remained thin. In practice, that makes much of today’s long-term daily melatonin use technically an off-label habit, even though it’s treated socially about as casually as a cup of chamomile tea before bed. That’s precisely the gap the 2026 study starts to probe — and even as a preliminary finding, the result suggests that gap mattered more than assumed.
Known side effects versus the new open question
Before this study, melatonin was already considered fairly safe for short-term use, with mild, well-documented side effects: residual morning grogginess, headache, dizziness, and more vivid or intense dreams are among the most commonly reported. What had already been generating debate among sleep researchers, even before the 2026 news broke, was the specific combination of daily long-term use with doses frequently far above what research has tested — a scenario in which long-term safety data simply hasn’t been robust enough to fully reassure anyone. The heart failure finding didn’t come out of nowhere; it adds to a running list of questions the scientific community had already been asking about what happens in the body after years of continuous exposure to a hormone that the body itself naturally regulates in much smaller quantities, for a limited window each night. What makes the 2026 finding notable isn’t that it’s the first time melatonin’s cardiovascular effects have come under scrutiny — it’s the scale of the tracked population and the specific, hard clinical endpoint (a heart failure diagnosis, not just a lab marker) that gives the signal more weight than a typical small pharmacology study would carry.
What sleep doctors reach for first, before any pill: CBT-I
If long-term melatonin use isn’t the first-line treatment recommended by sleep medicine societies, what is? The consistent answer from the most respected guidelines is Cognitive Behavioral Therapy for Insomnia, known as CBT-I. Unlike a pill, CBT-I works directly on the thoughts and behaviors that keep insomnia going: it identifies anxious beliefs about sleep (“if I don’t get eight hours, tomorrow will be a disaster”), rebuilds a person’s relationship with their bed and bedroom, and uses techniques like sleep restriction and stimulus control to re-establish a healthy association between lying down and actually falling asleep. Comparative studies show CBT-I tends to work about as well as medication in the short term and better in the long run, without the pharmacological risks tied to extended use of any substance. It’s typically delivered by psychologists or therapists trained in the method, over the course of a few weeks, in person or through structured online programs, which makes it more accessible than a lot of people assume.
Sleep habits with real evidence behind them
Alongside CBT-I, there’s a set of simple habits with consistent evidence supporting them: keeping a fixed sleep and wake schedule every day, including weekends; getting natural light exposure in the morning, which helps calibrate the body’s own circadian clock without relying on an outside supplement; cutting off caffeine by early-to-mid afternoon; cutting back on long daytime naps, which tend to steal sleep pressure away from the night; and practicing stimulus control — using the bed only for sleep, and getting up after about 20 minutes of not being able to fall asleep rather than lying there stewing in frustration, returning only once genuine sleepiness sets in. The bedroom environment matters more than it gets credit for, too: blocking out stray light and unwanted noise cuts down on nighttime awakenings many people don’t even register happening. A simple pairing like a sleep mask with earplugs won’t replace any of these behavioral changes, but it works as a cheap, immediate complement for anyone who’s already adjusted their routine and is still dealing with streetlight glare, a partner on a different schedule, or a noisy neighbor — without adding another substance into the body at all. Consistency tends to matter more than any single tweak: most of these habits take one to two weeks of steady practice before their effect on sleep becomes noticeable, which is longer than most people give them before giving up and reaching for a supplement instead.
For a broader look at what typically sits behind restless nights, our guide on insomnia causes and how to sleep better covers common triggers and the mistakes people often make trying to fix the problem alone.
Taking melatonin every night? Here’s what to actually do with this news
If you’re someone who’s relied on melatonin for months or years as part of a sleep routine, the most sensible reaction isn’t to quit cold turkey on your own — abruptly dropping an established sleep habit without a plan can make insomnia worse in the short term, and that’s not what this research is asking anyone to do. The practical move is to talk to a doctor or sleep specialist about your specific history, bringing concrete questions into that conversation. A few worth writing down before the appointment:
- How long have I been using melatonin, and at what exact dose (worth double-checking the specific product’s label)?
- Do I have other cardiovascular risk factors, such as high blood pressure, elevated cholesterol, diabetes, or a family history of heart disease?
- Does it make sense in my case to explore CBT-I or another non-drug approach to insomnia?
- If I decide to stop, is there a safe way to taper the dose gradually rather than quitting outright?
That kind of decision is individual and depends on health context only a professional can weigh accurately — this article isn’t a substitute for that conversation, just a way to walk into it better informed and less alarmed. The 2026 finding is a real signal worth taking seriously, but by the researchers’ own account, it’s an open chapter, not a final verdict on a hormone the body already makes for itself every night.
If you’re into this kind of trivia, you’ll probably also enjoy t-maxxing.
Recommended products
Sleep Mask and Earplugs Set — a simple, non-pharmacological way to block out light and noise while you work on evidence-based sleep habits, without adding another substance to the nightstand.
Disclosure: this is our tracked affiliate link.
Reading this with a bottle of melatonin on the nightstand? Bookmark it and bring the right questions to your next doctor’s visit.